199 related articles for article (PubMed ID: 22701683)
1. Effects of valacyclovir on markers of disease progression in postpartum women co-infected with HIV-1 and herpes simplex virus-2.
Roxby AC; Drake AL; Ongecha-Owuor F; Kiarie JN; Richardson B; Matemo DN; Overbaugh J; Emery S; John-Stewart GC; Wald A; Farquhar C
PLoS One; 2012; 7(6):e38622. PubMed ID: 22701683
[TBL] [Abstract][Full Text] [Related]
2. Valacyclovir suppressive therapy reduces plasma and breast milk HIV-1 RNA levels during pregnancy and postpartum: a randomized trial.
Drake AL; Roxby AC; Ongecha-Owuor F; Kiarie J; John-Stewart G; Wald A; Richardson BA; Hitti J; Overbaugh J; Emery S; Farquhar C
J Infect Dis; 2012 Feb; 205(3):366-75. PubMed ID: 22147786
[TBL] [Abstract][Full Text] [Related]
3. Infant safety during and after maternal valacyclovir therapy in conjunction with antiretroviral HIV-1 prophylaxis in a randomized clinical trial.
Drake AL; Roxby AC; Kiarie J; Richardson BA; Wald A; John-Stewart G; Farquhar C
PLoS One; 2012; 7(4):e34635. PubMed ID: 22509337
[TBL] [Abstract][Full Text] [Related]
4. Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus.
Nagot N; Ouédraogo A; Foulongne V; Konaté I; Weiss HA; Vergne L; Defer MC; Djagbaré D; Sanon A; Andonaba JB; Becquart P; Segondy M; Vallo R; Sawadogo A; Van de Perre P; Mayaud P;
N Engl J Med; 2007 Feb; 356(8):790-9. PubMed ID: 17314338
[TBL] [Abstract][Full Text] [Related]
5. High-dose valacyclovir HSV-2 suppression results in greater reduction in plasma HIV-1 levels compared with standard dose acyclovir among HIV-1/HSV-2 coinfected persons: a randomized, crossover trial.
Mugwanya K; Baeten JM; Mugo NR; Irungu E; Ngure K; Celum C
J Infect Dis; 2011 Dec; 204(12):1912-7. PubMed ID: 21998479
[TBL] [Abstract][Full Text] [Related]
6. HSV suppression reduces seminal HIV-1 levels in HIV-1/HSV-2 co-infected men who have sex with men.
Zuckerman RA; Lucchetti A; Whittington WL; Sánchez J; Coombs RW; Magaret A; Wald A; Corey L; Celum C
AIDS; 2009 Feb; 23(4):479-83. PubMed ID: 19169140
[TBL] [Abstract][Full Text] [Related]
7. The effect of valacyclovir on HIV and HSV-2 in HIV-infected persons on antiretroviral therapy with previously unrecognised HSV-2.
Van Wagoner N; Geisler WM; Bachmann LH; Hook EW
Int J STD AIDS; 2015 Jul; 26(8):574-81. PubMed ID: 25147236
[TBL] [Abstract][Full Text] [Related]
8. A randomized controlled pilot trial of valacyclovir for attenuating inflammation and immune activation in HIV/herpes simplex virus 2-coinfected adults on suppressive antiretroviral therapy.
Yi TJ; Walmsley S; Szadkowski L; Raboud J; Rajwans N; Shannon B; Kumar S; Kain KC; Kaul R; Tan DH
Clin Infect Dis; 2013 Nov; 57(9):1331-8. PubMed ID: 23946220
[TBL] [Abstract][Full Text] [Related]
9. Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial.
Zuckerman RA; Lucchetti A; Whittington WL; Sanchez J; Coombs RW; Zuñiga R; Magaret AS; Wald A; Corey L; Celum C
J Infect Dis; 2007 Nov; 196(10):1500-8. PubMed ID: 18008230
[TBL] [Abstract][Full Text] [Related]
10. High-dose valacyclovir decreases plasma HIV-1 RNA more than standard-dose acyclovir in persons coinfected with HIV-1 and HSV-2: a randomized crossover trial.
Perti T; Saracino M; Baeten JM; Johnston C; Diem K; Ocbamichael N; Huang ML; Selke S; Magaret A; Corey L; Wald A
J Acquir Immune Defic Syndr; 2013 Jun; 63(2):201-8. PubMed ID: 23542637
[TBL] [Abstract][Full Text] [Related]
11. Impact of suppressive herpes therapy on genital HIV-1 RNA among women taking antiretroviral therapy: a randomized controlled trial.
Ouedraogo A; Nagot N; Vergne L; Konate I; Weiss HA; Defer MC; Foulongne V; Sanon A; Andonaba JB; Segondy M; Mayaud P; Van de Perre P
AIDS; 2006 Nov; 20(18):2305-13. PubMed ID: 17117016
[TBL] [Abstract][Full Text] [Related]
12. Short communication: T cell activation in HIV-1/herpes simplex virus-2-coinfected Kenyan women receiving valacyclovir.
Roxby AC; Liu AY; Drake AL; Kiarie JN; Richardson B; Lohman-Payne BL; John-Stewart GC; Wald A; De Rosa S; Farquhar C
AIDS Res Hum Retroviruses; 2013 Jan; 29(1):94-8. PubMed ID: 22852760
[TBL] [Abstract][Full Text] [Related]
13. Can herpes simplex virus type 2 suppression slow HIV disease progression: a study protocol for the VALacyclovir In Delaying Antiretroviral Treatment Entry (VALIDATE) trial.
Tan DH; Raboud JM; Kaul R; Grinsztejn B; Cahn P; Walmsley SL
Trials; 2010 Nov; 11():113. PubMed ID: 21106086
[TBL] [Abstract][Full Text] [Related]
14. Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial.
Lingappa JR; Baeten JM; Wald A; Hughes JP; Thomas KK; Mujugira A; Mugo N; Bukusi EA; Cohen CR; Katabira E; Ronald A; Kiarie J; Farquhar C; Stewart GJ; Makhema J; Essex M; Were E; Fife KH; de Bruyn G; Gray GE; McIntyre JA; Manongi R; Kapiga S; Coetzee D; Allen S; Inambao M; Kayitenkore K; Karita E; Kanweka W; Delany S; Rees H; Vwalika B; Magaret AS; Wang RS; Kidoguchi L; Barnes L; Ridzon R; Corey L; Celum C;
Lancet; 2010 Mar; 375(9717):824-33. PubMed ID: 20153888
[TBL] [Abstract][Full Text] [Related]
15. Maternal valacyclovir and infant cytomegalovirus acquisition: a randomized controlled trial among HIV-infected women.
Roxby AC; Atkinson C; Asbjörnsdóttir K; Farquhar C; Kiarie JN; Drake AL; Wald A; Boeckh M; Richardson B; Emery V; John-Stewart G; Slyker JA
PLoS One; 2014; 9(2):e87855. PubMed ID: 24504006
[TBL] [Abstract][Full Text] [Related]
16. The effect of daily valacyclovir suppression on herpes simplex virus type 2 viral shedding in HSV-2 seropositive subjects without a history of genital herpes.
Sperling RS; Fife KH; Warren TJ; Dix LP; Brennan CA
Sex Transm Dis; 2008 Mar; 35(3):286-90. PubMed ID: 18157071
[TBL] [Abstract][Full Text] [Related]
17. Oral antiviral therapy for prevention of genital herpes outbreaks in immunocompetent and nonpregnant patients.
Le Cleach L; Trinquart L; Do G; Maruani A; Lebrun-Vignes B; Ravaud P; Chosidow O
Cochrane Database Syst Rev; 2014 Aug; 2014(8):CD009036. PubMed ID: 25086573
[TBL] [Abstract][Full Text] [Related]
18. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2.
Celum C; Wald A; Lingappa JR; Magaret AS; Wang RS; Mugo N; Mujugira A; Baeten JM; Mullins JI; Hughes JP; Bukusi EA; Cohen CR; Katabira E; Ronald A; Kiarie J; Farquhar C; Stewart GJ; Makhema J; Essex M; Were E; Fife KH; de Bruyn G; Gray GE; McIntyre JA; Manongi R; Kapiga S; Coetzee D; Allen S; Inambao M; Kayitenkore K; Karita E; Kanweka W; Delany S; Rees H; Vwalika B; Stevens W; Campbell MS; Thomas KK; Coombs RW; Morrow R; Whittington WL; McElrath MJ; Barnes L; Ridzon R; Corey L;
N Engl J Med; 2010 Feb; 362(5):427-39. PubMed ID: 20089951
[TBL] [Abstract][Full Text] [Related]
19. Herpes simplex virus type 2, genital ulcers and HIV-1 disease progression in postpartum women.
Roxby AC; Drake AL; John-Stewart G; Brown ER; Matemo D; Otieno PA; Farquhar C
PLoS One; 2011; 6(5):e19947. PubMed ID: 21637835
[TBL] [Abstract][Full Text] [Related]
20. Effect of valacyclovir on viral shedding in immunocompetent patients with recurrent herpes simplex virus 2 genital herpes: a US-based randomized, double-blind, placebo-controlled clinical trial.
Fife KH; Warren TJ; Ferrera RD; Young DG; Justus SE; Heitman CK; Burroughs SM
Mayo Clin Proc; 2006 Oct; 81(10):1321-7. PubMed ID: 17036557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]